Inactief instrument

Andere talen Regulus Therapeutics Inc Nasdaq

Aandelen

US75915K1016

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	06/05
Regulus Therapeutics Advances to Cohort 4 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	06/05
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series	30/04
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Regulus: Q4 Earnings Snapshot	21/03
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates	21/03
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP	14/03
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors	14/03
Top Midday Gainers	12/03
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise	12/03
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	12/03
Top Premarket Gainers	12/03
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity	12/03
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	12/03
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	12/03
Regulus Therapeutics Inc. announced that it expects to receive $100.000267 million in funding from a group of investors	11/03
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	02/01
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	02/01
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference	22/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Regulus Therapeutics Inc Nasdaq

Aandelen

US75915K1016

Andere talen

Filters